WEBULL
WebtradeDownload

Haleon (LSE:HLN) Stock May Be 40% Undervalued After Flu Demand Outlook

Simply Wall St · 2d ago

Haleon has delivered a 17.8% share price return over the past three years, and fresh earnings optimism around cold and flu season has pushed the story back into focus. The question for you is whether that recent enthusiasm lines up with what the company’s cash flows can reasonably justify.

  • Over a 3 year window, Haleon’s 17.8% return puts real weight on whether investors are now paying a price that accurately reflects the cash the business is expected to generate.
  • UBS’s higher earnings expectations linked to an early uptick in flu incidence may support stronger medium term cash flows for Haleon if health related demand stays resilient.
  • Prefer to judge Haleon on earnings? See what Haleon's 20.2x P/E says about the price.

The issue now is whether Haleon’s current share price is aligned with the intrinsic value suggested by its projected cash flows under a Discounted Cash Flow (DCF) lens.

If you want a broader watchlist while you assess Haleon’s cash flows, a focused stock screen is a useful second step. You can start with 6 high quality undervalued stocks.

Is Haleon Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) approach takes Haleon’s expected future cash generation and discounts it back to today. On this model, the group is coming off last twelve month free cash flow of about £2.48b, with the projection set pointing to free cash flow that broadly grows rather than shrinking through the next decade.

Haleon’s cash profile in the DCF is not built on rapid expansion. It leans on relatively steady increases in free cash flow, which in this analysis supports an intrinsic value outcome that sits substantially above the current £3.73 share price. UBS raising its 2027 earnings forecasts on the back of an early flu uptick points to a supportive near term backdrop. However, the gap between the discounted cash flow value and today’s market price suggests that optimism in the headlines has not fully carried through into the valuation. Find out what Haleon could be worth using our Discounted Cash Flow (DCF) estimate.

The Haleon Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Haleon's DCF puzzle leaves off by spelling out which paths for growth, profitability and earnings would need to play out for the stock to be worth materially more or less than today’s market price on the Community page. Each scenario links its number to a clear view on how Haleon's expansion prospects, margins and risk profile might evolve, giving you a reference point you can revisit as fresh information comes through.

Community views on Haleon are split between those who see more left in the tank and those who think the current price already builds in most of the good news.

Bull case: 28% undervalued

"Extending Haleon’s premium therapeutic oral health portfolio, including sensitivity and gum health products and higher priced formats such as Sensodyne Clinical White and Clinical Repair, into more markets and price tiers could shift mix further toward higher margin segments…"

Discover why this Narrative puts Haleon at 28% undervalued.

Bear case: 21% overvalued

"Although Haleon continues to talk up premium, clinically supported oral health launches that have historically outgrown the wider category, the group is still only delivering 2.6% organic revenue growth in the first half of 2026 against a 4% to 6% ambition…"

Explore why this Narrative puts Haleon at 21% overvalued.

One more piece of the Haleon story to check before you move on

Price and cash flows only tell part of Haleon’s story, because separate checks have flagged specific areas of concern that deserve your attention before you get comfortable with the risk profile. Take a closer look at 1 warning sign before settling on a valuation.